"FASS - Presentation and discussion of Good Practice Example", presented by Ann Maliniak, Swedish Association of the Pharmaceutical Industry (LIF), Sweden, at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
Reaching a public audience on medicines development: Anna ZawadaNowgen
"Reaching a public audience on medicines development", presented by Anna Zawada, Agency for Health Technology Assessment at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
EUPATI’s framework on Informing the “health-interested” public about medicine...Nowgen
"EUPATI's framework on Informing the “health-interested” public objectively and comprehensively about medicines R&D", presented by Jan Geissler at the EUPATI 2014 Workshop in Warsaw
What were the success factors in this morning good practices examples, what a...Nowgen
"What were the success factors in this morning good practices examples", Results from Workgroup 2 presented by at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI
"Patient involvement in medicines R&D: Bringing to life with EUPATI", presented by Jan Geissler, EUPATI Director, at the EUPATI 2013 Conference on 19 April 2013
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI
"Patient involvement in medicines R&D: Here we are, and where we want to be in 2020" by Nicola Bedlington, Executive Director of European Patients' Forum and Coordinator of the EUPATI project, at the EUPATI 2013 Conference on 19 April 2013.
Reaching a public audience on medicines development: Anna ZawadaNowgen
"Reaching a public audience on medicines development", presented by Anna Zawada, Agency for Health Technology Assessment at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
EUPATI’s framework on Informing the “health-interested” public about medicine...Nowgen
"EUPATI's framework on Informing the “health-interested” public objectively and comprehensively about medicines R&D", presented by Jan Geissler at the EUPATI 2014 Workshop in Warsaw
What were the success factors in this morning good practices examples, what a...Nowgen
"What were the success factors in this morning good practices examples", Results from Workgroup 2 presented by at EUPATI 2014 Workshop on 2 April 2014 in Warsaw
EUPATI 2013 Conference: Patient involvement in medicines R&D: Bringing to li...EUPATI
"Patient involvement in medicines R&D: Bringing to life with EUPATI", presented by Jan Geissler, EUPATI Director, at the EUPATI 2013 Conference on 19 April 2013
EUPATI 2013 Conference: Vision on Patient involvement in medicines R&D: Here...EUPATI
"Patient involvement in medicines R&D: Here we are, and where we want to be in 2020" by Nicola Bedlington, Executive Director of European Patients' Forum and Coordinator of the EUPATI project, at the EUPATI 2013 Conference on 19 April 2013.
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...EUPATI
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involvement in Medicines R&D, “Bring to life with EUPATI examples”, by Niels Westergaard, PhD, DSc Biopeople, University of Copenhagen, Denmark
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...EUPATI
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013, presented by Jan Geissler (@jangeissler), Director EUPATI (@EUPATIents) at the IMI's "Patient Focus" meeting, convening patient leaders from across Europe
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015jangeissler
Overview and Status Quo of the European Patients Academy (EUPATI) project, presented by EUPATI Director Jan Geissler at the EMA Patient and Consumer Working Party (PCWP) meeting in London on 26 Nov 2015
Workshop 4 - Research
"Presentation of the RD Platform fact finding study
on the trends and determinants of rare disease research"
Virginie Hivert, Orphanet, France
AzCI presents: Working with Your Demographic Market (in Orphan Drug Development)AnitaBell
Arizona Center for Innovation (AzCI) presents: Working with Your Demographic Market (in orphan drug development)
This presentation is part of a series developed for a workshop on "How to Navigate the Biotech Regulatory Process"
The Arizona Center for Innovation is an incubator and innovation center and provides resources in support of startups getting to the next level and become successful enterprises.
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involv...EUPATI
EUPATI 2013 Conference: Building Knowledge & Competences for Patients’ Involvement in Medicines R&D, “Bring to life with EUPATI examples”, by Niels Westergaard, PhD, DSc Biopeople, University of Copenhagen, Denmark
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 ...EUPATI
European Patients' Academy - Presentation at IMI Patient Focus Meeting on 12 June 2013, presented by Jan Geissler (@jangeissler), Director EUPATI (@EUPATIents) at the IMI's "Patient Focus" meeting, convening patient leaders from across Europe
EUPATI Status Update at EMA PCWP Meeting, 26 Nov 2015jangeissler
Overview and Status Quo of the European Patients Academy (EUPATI) project, presented by EUPATI Director Jan Geissler at the EMA Patient and Consumer Working Party (PCWP) meeting in London on 26 Nov 2015
Workshop 4 - Research
"Presentation of the RD Platform fact finding study
on the trends and determinants of rare disease research"
Virginie Hivert, Orphanet, France
AzCI presents: Working with Your Demographic Market (in Orphan Drug Development)AnitaBell
Arizona Center for Innovation (AzCI) presents: Working with Your Demographic Market (in orphan drug development)
This presentation is part of a series developed for a workshop on "How to Navigate the Biotech Regulatory Process"
The Arizona Center for Innovation is an incubator and innovation center and provides resources in support of startups getting to the next level and become successful enterprises.
Michael Skynner - 'Aunando esfuerzos para el futuro de la investigación en en...Fundación Ramón Areces
'Aunando esfuerzos para el futuro de la investigación en enfermedades poco frecuentes'. Éste fue el lema de la jornada que tuvo lugar el 27 de abril de 2015, en la Fundación Ramón Areces. Organizada en colaboración con la Fundación Pfizer y el Instituto de Salud Carlos III, reunió a algunos de los principales expertos en Enfermedades raras para analizar el estado de la investigación.
Polypharmacy and deprescribing safely: a patient-centred method, Professor Nina Barnett Consultant Pharmacist,Care of Older People, London North West Healthcare NHS Trust Medicines Use and Safety Team, Specialist Pharmacy Service
Visiting Professor, Institute of Pharmaceutical Science,
Kings College London
A Rare International Dialogue (Saturday May 11, 2019)
Drivers of Drug Development – Regulatory Collaboration
European regulatory approaches to drugs for rare diseases - Daniel O’Connor, European Medicines Agency/Medicines and Healthcare products Regulatory Agency, UK
IMS Health Real-World Evidence Solutions at ISPOR November 2015IMSHealthRWES
Welcome to the IMS Health Real-World Evidence (RWE) Solutions program of activities at the forthcoming ISPOR 18th Annual European Congress in Milan. We invite you to join us at more than 70 presentations that spotlight exciting innovations and applications of outcomes research and RWE. And please visit us at our booth to learn more about our pioneering efforts including the e360TM technology suite, RWD Catalogue with 1,800+ data sources identified, and the newly launched RWE Dictionary. Full details of our ISPOR schedule can be found in the brochure.
Involving People: Patients, Participants & Consumers in U.K.Cancer Research (...Nowgen
Involving People: Patients, Participants & Consumers in U.K.Cancer Research, presented by Richard Stephens at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Working with young people to shape research – reaping the benefits & the impo...Nowgen
"Working with young people to shape research – reaping the benefits & the importance of education in this setting", presented by Jenny Preston, Medicines for Children Research Network, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Patients at the Centre for Health Research – Patient, Carer and Public Invol...Nowgen
"Patients at the Centre for Health Research –
Patient, Carer and Public Involvement in NICE Decision-Making", presented by Victoria Thomas, NICE, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
INVOLVE perspectives on learning and development (Sarah Buckland, INVOLVE)Nowgen
"INVOLVE perspectives on learning and development", presented by Sarah Buckland, INVOLVE, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Patient involvement in clinical research and long term conditions -what can b...Nowgen
"Patient involvement in clinical research and long term conditions -what can be achieved by working in partnership", presented by Dr. J. Paul Schofield, ABPI, at EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Patients at the core of medical research & development (Emma Law, Scottish De...Nowgen
"Patients at the core of medical research & development", presented by Emma Law, Scottish Dementia Clinical Research Network, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Bringing the patient voice into GSK for educational, awareness and patient ce...Nowgen
"Bringing the patient voice into GlaxoSmithKline for educational, awareness and patient centred decisions within medicine development", presented by Kay Warner, Global Manager, Focus on the Patient, GlaxoSmithKline, at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
Patient involvement in medicines development – the views of patients and key ...Nowgen
"EUPATI – EU: An overview", held by Bella Starling & Suzanne Parsons (EUPATI / Nowgen) at the EUPATI-UK Network Conference on 6 March 2014 in Leeds, UK
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Light House Retreats: Plant Medicine Retreat Europe
FASS - Presentation and discussion of Good Practice Example: Maliniak
1. Ann Maliniak
Swedish Association of the Pharmaceutical Industry (LIF), Sweden
EUPATI 2014 Workshop, 2 April 2014, Warsaw
Break-Out Group
Presentation and discussion of Good Practice Example
LIF
The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n 115334, resources of which are composed
of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies.
2. Primary source of medicine information
Ann Maliniak
The Swedish Association of the Pharmaceutical Industry
EUPATI workshop 2014-04-02
3. Content
LIF – the Swedish Association of the
Pharmaceutical Industry
History of FASS
FASS – Information about medicines
Coming news
3
5. The Swedish Association
of the Pharmaceutical Industry
Association for the research-based
pharmaceutical industry in Sweden
80 companies:
~ 80 % of the medicines
~ 13 000 employees
~ 1,5 billion € in R&D
Voice for an efficient and modern medical care
A service organization for member companies
5
7. FASS – Information about medicines
Available 24/7
Over 3 million visits per month
(Sweden’s population: ~ 9 million)
Always updated
High quality - well recognized
Free of charge
All documents approved by authorities
7
9. Key to success
Unique: both for professionals and
the general public
All prescription and non-prescription medicine
Medical guide on diseases and symptoms
Patient organisations
Adapted for users with disabilities
• Lexicon
• Text to speach
• Braille 9
10.
11. FASS database
Information on medicines added and uppdated
directly by ~ 200 companies
Also available on smart phones and tablets
11
14. Coming on FASS
Short movies about medicine
• Presents how medicines are developed
and reach the place where it will deliver the effect
• Placed on Fass for better understanding and a
safer use of medicine
Welcome to visit the poster session!
142014-04-02
15. Coming on FASS, cont.
In-stock status
• Finding pharmacies having a specific medicine in stock
• Collaboration with the Swedish Pharmacy Association
– Re-regulation of Swedish Pharmacies 2009
– Several new players and pharmacies
15
16. FASS on Tour 2012-2013
Louisiana, Denmark - New Nordic
29. June - 21. Oct 2012
Kennedy Center, Washington DC - Nordic Cool
19. Feb - 17. March 2013
16